Clinical Trial Update: RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) [Phase 2]

View source ↗

Summary

A Phase 2 pharmacodynamic study of RGX-314 for neovascular age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• RGX-314

Snippet

Sponsor: AbbVie | Conditions: Neovascular Age-related Macular Degeneration, Wet Macular Degeneration | Phase 2 | Status: COMPLETED